E. Ohman J or Asset Management AB Invests $2 Million in Vera Therapeutics, Inc. $VERA

E. Ohman J or Asset Management AB purchased a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 39,500 shares of the company’s stock, valued at approximately $2,000,000. E. Ohman J or Asset Management AB owned 0.06% of Vera Therapeutics at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. GAMMA Investing LLC grew its position in Vera Therapeutics by 50.5% during the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after purchasing an additional 236 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Vera Therapeutics in the second quarter valued at $51,000. Virtus Investment Advisers LLC boosted its position in shares of Vera Therapeutics by 14.8% in the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock worth $98,000 after buying an additional 539 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Vera Therapeutics by 192.9% in the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after buying an additional 2,757 shares during the period. Finally, Ameritas Investment Partners Inc. grew its holdings in shares of Vera Therapeutics by 13.3% during the second quarter. Ameritas Investment Partners Inc. now owns 5,254 shares of the company’s stock valued at $124,000 after buying an additional 615 shares in the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Bank of America upped their price target on Vera Therapeutics from $48.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, December 19th. TD Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a research note on Friday, December 5th. The Goldman Sachs Group upped their target price on Vera Therapeutics from $55.00 to $95.00 and gave the company a “buy” rating in a report on Friday, December 19th. Wedbush increased their price target on shares of Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Vera Therapeutics in a report on Wednesday, November 26th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $81.45.

Vera Therapeutics Stock Down 2.4%

VERA stock opened at $39.75 on Wednesday. The firm has a market cap of $2.84 billion, a PE ratio of -8.53 and a beta of 1.17. Vera Therapeutics, Inc. has a 1 year low of $18.53 and a 1 year high of $56.05. The company has a fifty day simple moving average of $42.73 and a 200 day simple moving average of $37.82. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.12.

Vera Therapeutics (NASDAQ:VERA) last posted its earnings results on Thursday, February 26th. The company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.34) by ($0.05). During the same period in the previous year, the business earned ($0.72) EPS. Sell-side analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Insider Activity at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 16,925 shares of the stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $710,511.50. Following the transaction, the chief executive officer owned 257,163 shares of the company’s stock, valued at approximately $10,795,702.74. This represents a 6.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO David Lee Johnson sold 2,579 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $108,266.42. Following the completion of the sale, the chief operating officer owned 45,727 shares of the company’s stock, valued at approximately $1,919,619.46. This trade represents a 5.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 33,490 shares of company stock worth $1,405,910 in the last 90 days. Insiders own 16.30% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.